Biogen Inc. (BIIB)
| Market Cap | 41.46B |
| Revenue (ttm) | 14.26B |
| Net Income (ttm) | 5.08B |
| Shares Out | 156.90M |
| EPS (ttm) | 30.38 |
| PE Ratio | 8.87 |
| Forward PE | 10.38 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $269.44 |
| Previous Close | $270.12 |
| Change ($) | -0.68 |
| Change (%) | -0.25% |
| Day's Open | 270.34 |
| Day's Range | 268.48 - 272.71 |
| Day's Volume | 691,169 |
| 52-Week Range | 236.26 - 355.63 |
The Oracle of Omaha may give these brand-name companies the boot from Berkshire Hathaway's portfolio.
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.
Apple (AAPL) is collaborating with Biogen to test whether the Apple Watch and iPhone can collect and transmit biometric data on cognitive performance.
New York, New York--(Newsfile Corp. - January 11, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alle...
Biogen Inc. (BIIB) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
Biogen Inc. (BIIB) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
Exact Sciences (NASDAQ: EXAS) shares are trading higher after the company issued fourth-quarter sales guidance above analyst estimates. Exact Sciences is a molecular diagnostics company focuse...
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securiti...
Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen the...
Biogen has an impressive portfolio of assets, and the company is heavily focused on R&D with major drugs like Aducanumab. The company's impressive drug portfolio has the potential to make 2021...
New York, New York--(Newsfile Corp. - January 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the ...
Biogen Inc (NASDAQ: BIIB), which has a fairly solid neurology-focused pipeline, announced Monday a collaboration with tech giant Apple Inc (NASDAQ: AAPL). What Happened: Cambridge, Massachuset...
New York, New York--(Newsfile Corp. - January 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch an...
NEW YORK, NY / ACCESSWIRE / January 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded co...
New York, New York--(Newsfile Corp. - January 9, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion ...
LOS ANGELES--(BUSINESS WIRE)---- $BIIB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and c...
BENSALEM, Pa., Jan. 8, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on beha...
New York, New York--(Newsfile Corp. - January 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securi...
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study ...
New York, New York--(Newsfile Corp. - January 7, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion...
NEW YORK--(BUSINESS WIRE)-- #biogen--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the Unite...
As the Covid-19 vaccines from Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) continue to be distributed throughout the U.S. and internationally to doctors, nurses, the eld...
LOS ANGELES, Jan. 6, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise ac...
New York, New York--(Newsfile Corp. - January 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion ...
New York, New York--(Newsfile Corp. - January 4, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors ...
LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class action fi...
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities cl...
Warren Buffett's investing track record is impressive -- but he's not always right.
Wide-Moat Stocks On Sale - The January 2021 Heat Map
If you want to increase your likelihood of finding stocks that could beat the market, one method is to choose stocks that rank highly on the "Magic Formula" criteria.
Today's the final day for tax-loss harvesting in 2020.
LOS ANGELES, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class acti...
NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you ...
New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investor...
These biotech stocks could sink or soar following some important approval decisions slated for the new year.
New York, New York--(Newsfile Corp. - December 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) all...
New York, New York--(Newsfile Corp. - December 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...
Boston, Massachusetts--(Newsfile Corp. - December 22, 2020) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Biogen Inc. (NADSAQ: BIIB). I...
Over halfway through the trading day on Tuesday, and the broad markets have yet to make up their minds.
BENSALEM, Pa., Dec. 22, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on beh...
NEW YORK, NY / ACCESSWIRE / December 22, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded c...
We believe that Biogen stock, a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. BIIB stock trades near $250 currently a...
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved a new intramuscular (IM) injection route of admini...
NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advise...
Each company has suffered a clinical failure recently, but this team-up could do good things for both.
This biotech giant is getting desperate to generate sales growth. Should investors be hopeful for a potential turnaround?
The company isn't standing still while its Alzheimer's drug is up in the air.
Biogen Inc has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kic...
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treati... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Sep 16, 1991 |
| CEO George Scangos | Employees 7,400 |
| Stock Exchange NASDAQ | Ticker Symbol BIIB |
Financial Performance
In 2019, Biogen's revenue was $14.38 billion, an increase of 6.88% compared to the previous year's $13.45 billion. Earnings were $5.89 billion, an increase of 32.90%.
Analyst Forecasts
According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 291.38, which is an increase of 8.14% from the latest price.